B.Riley reiterates USD 9.00 target for Aspen Aerogels stock
Published on 10/21/2026 at 03:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSUpcoming results and operating targets
- B.Riley reiterated a USD 9.00 target on October 7, 2026.
- Second-quarter revenue reached USD 49.85 million, up 32.00 percent quarter over quarter.
- Aspen Aerogels had a USD 441.5 million market capitalization as of October 20, 2026.
Aspen Aerogels (US04523Y1055) faces an October 22, 2026 earnings date after quarterly revenue guidance of USD 65.00-80.00 million. According to Investing.com, B.Riley reiterated a Buy rating and a USD 9.00 price target on October 7, 2026.
Three recent signals with figures
On August 6, 2026, Aspen Aerogels reported second-quarter revenue of USD 49.85 million against a USD 41.61 million forecast, according to Investing.com. On October 6, 2026, Benzinga reported that management expected third-quarter revenue of USD 65 million to USD 80 million and adjusted EBITDA of USD 7 million to USD 15 million. On October 7, 2026, B.Riley maintained its USD 9.00 target, a figure carried by the Investing.com analyst table.
What does the USD 9.00 target imply?
The target sits 68.86 percent above the USD 5.33 NYSE price dated October 20, 2026. The operating case depends on conversion of the revenue guide into profit, because the second-quarter adjusted EBITDA was negative USD 6.6 million, although that improved from negative USD 12.7 million in the prior quarter, according to Benzinga.
Dates and operating constraints
The next substantiated corporate date is October 22, 2026, when Aspen Aerogels is scheduled to report its next results. Management also said on October 6, 2026 that full production capacity at the East Providence plant was expected to return during the first half of 2027, while second-quarter cash, cash equivalents and restricted cash stood at USD 153.4 million.
Valuation carries a clear risk
On the NYSE, the stock last stood at USD 5.33 on October 20, 2026. The same dated market overview placed the 52-week range at USD 2.30-8.64 and market capitalization at USD 441.5 million. The next results will test whether the guidance range can narrow the gap between revenue growth and profitability.
Latest market reports: Market report S&P 500.
